

Curriculum Vitae

Personal information

Konstantin Weber-Lassalle

Work experience

04/2023-present; non-clinical assessor; Federal institute for drugs and medical devices; Germany; drug approval, reproductive and developmental toxicology

04/2015-04/2021; research associate; University hospital Cologne, center for familial breast and ovarian cancer, Germany, research and drug safety

06/2014-12/2014; internship, master studies; Federal institute for drugs and medical devices; Germany; research

03/2014-05/2014; internship; Technical University Kaiserslautern, Germany, research

08/2013-10/2013; internship; Merck Serono; Germany, non-clinical safety, alternative assays

02/2013-04/2013; internship; Boehringer Ingelheim, Germany, non-clinical safety

03/2011-07/2011; internship, bachelor studies; University hospital Bonn, Institute for medical microbiology, immunology and parasitology, research

Education and training

10/2016-09/2022; PhD, University hospital Cologne, center for familial breast and ovarian cancer, Germany; research and drug safety, laboratory work, preparation and submission of publications

04/2022-05/2022; IPMA basic certification to ICB4 for project manager; German association for project management e.V., Germany

06/2018-06/2018; Qualification of clinical study director; center for clinical studies Cologne, Germany

10/2012-03/2015; MSc. in Toxicology; Technical University Kaiserslautern, Germany

10/2011-09/2012; BSc. Chemistry; Rheinische-Friedrich-Wilhelms University, Germany

10/2008-09/2011; BSc. in applied biology; Hochschule Bonn-Rhein-Sieg, Germany

08/1998-06/2007; high school diploma; Beethoven-Gymnasium Bonn, Germany

Additional information

Publications

Borde J, Laitman Y, Blümcke B, Niederacher D, Weber-Lassalle K, Sutter C, Rump A, Arnold N, Wang-Gohrke S, Horváth J, Gehrig A, Schmidt G, Dutranoy V, Ramser J, Hentschel J, Meindl A, Schroeder C, Wappenschmidt B, Engel C, Kuchenbaecker K, Schmutzler RK, Friedman E, Hahnen E, Ernst C. Polygenic risk scores indicate extreme ages at onset of breast cancer in female BRCA1/2 pathogenic variant carriers. *BMC Cancer*. 2022 Jun 27;22(1):706. doi: 10.1186/s12885-022-09780-1.

Weber-Lassalle K, Ernst C; et al. Clonal hematopoiesis-associated gene mutations in a clinical cohort of 448 patients with ovarian cancer. *Journal of the National Cancer Institute* 2021 Dec 28;djab231. doi: 10.1093/jnci/djab231.

Borde J, Ernst C, Wappenschmidt B, Niederacher D, Weber-Lassalle K, Schmidt G, Hauke J, Quante AS, Weber-Lassalle N, Horváth J, Pohl-Rescigno E, Arnold N, Rump A, Gehrig A, Hentschel J, Faust U, Dutranoy V, Meindl A, Kuzyakova M, Wang-Gohrke S, Weber BHF, Sutter C, Volk AE, Giannakopoulou O, Lee A, Engel C, Schmidt MK, Antoniou AC, Schmutzler RK, Kuchenbaecker K, Hahnen E. Performance of Breast Cancer Polygenic Risk Scores in 760 Female CHEK2 Germline Mutation Carriers. *J Natl Cancer Inst*. 2021 Jul 1;113(7):893-899. doi: 10.1093/jnci/djaa203.

Weber-Lassalle N*, Borde J*, Weber-Lassalle K* et al. Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer. *Breast Cancer Research* 2019 Apr 29;21(1):55.

Weber-Lassalle K*, Harter P* et al. Diagnosis of Li-Fraumeni Syndrome: Differentiating TP53 germline mutations from clonal hematopoiesis. *Human Mutation* 39, 2040–2046 (2018)

Hauke J, Horvath J, Groß E, Gehrig A, Honisch E, Hackmann K, Schmidt G, Arnold N, Faust U, Sutter C, Hentschel J, Wang-Gohrke S, Smogavec M, Weber BHF, Weber-Lassalle N, Weber-Lassalle K, Borde J, Ernst C, Altmüller J, Volk AE, Thiele H, Hübner V, Nürnberg P, Keupp K, Versmold B, Pohl E, Kubisch C, Grill S, Paul V, Herold N, Lichey N, Rhiem K, Ditsch N, Ruckert C, Wappenschmidt B, Auber B, Rump A, Niederacher D, Haaf T, Ramser J, Dworniczak B, Engel C, Meindl A, Schmutzler RK, Hahnen E. Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer. *Cancer Med*. 2018 Apr;7(4):1349-1358. doi: 10.1002/cam4.1376. Epub 2018 Mar 9.

Weber-Lassalle N, Hauke J, Ramser J, Richters L, Groß E, Blümcke B, Gehrig A, Kahlert AK, Müller CR, Hackmann K, Honisch E, Weber-Lassalle K, Niederacher D, Borde J, Thiele H, Ernst C, Altmüller J, Neidhardt G, Nürnberg P, Klaschik K, Schroeder C, Platzer K, Volk AE, Wang-Gohrke S, Just W, Auber B, Kubisch C, Schmidt G, Horvath J, Wappenschmidt B, Engel C, Arnold N, Dworniczak B, Rhiem K, Meindl A, Schmutzler RK, Hahnen E. BRIP1 loss-of-

function mutations confer high risk for familial ovarian cancer, but not familial breast cancer. *Breast Cancer Res.* 2018 Jan 24;20(1):7. doi: 10.1186/s13058-018-0935-9.

Haas B*, Weber-Lassalle K*, Frötschl R & Eckstein N. Is sunitinib a Narrow Therapeutic Index Drug? - A systematic review and in vitro toxicology-analysis of Sunitinib vs. Imatinib in cells from different tissues. *Regulatory Toxicology and Pharmacology* 77, 25-34 (2016)

Berscheid A, Sass P, Weber-Lassalle K, Cheung A. L & Bierbaum G. Revisiting the genomes of the *Staphylococcus aureus* strains NCTC 8325 and RN4220. *International Journal of Medical Microbiology* 302, 84-7 (2012)

[Projects](#)

[Memberships](#)

[Other Relevant Information](#)